Differences in drug pharmacokinetics between East Asians and Caucasians and the role of genetic polymorphisms

Journal of Clinical Pharmacology

Volumn 44, Issue 10, 2004, Pages 1083-1105

  Kim, Kiman ^a   Johnson, Julie A ^a   Derendorf, Hartmut ^a  

^a UNIVERSITY OF FLORIDA   (United States)

Author keywords

Caucasians; East Asians; Genetic polymorphisms; Interethnic variability; Pharmacokinetics

Indexed keywords

ACENOCOUMAROL; CLOMIPRAMINE; CODEINE; CYTOCHROME P450 1A2; CYTOCHROME P450 2A6; CYTOCHROME P450 2C; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; DEBRISOQUINE; DESIPRAMINE; DEXTROMETHORPHAN; DIAZEPAM; DICLOFENAC; DIPHENHYDRAMINE; GLIPIZIDE; GLYCOPROTEIN P; HALOPERIDOL; IBUPROFEN; LOSARTAN; METOPROLOL; MULTIDRUG RESISTANCE PROTEIN 1; NORTRIPTYLINE; OMEPRAZOLE; PHENYTOIN; PROPRANOLOL; REBOXETINE; SPARTEINE; TOLBUTAMIDE; UNINDEXED DRUG; WARFARIN;

AREA UNDER THE CURVE; ASIAN; CAUCASIAN; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG TRANSPORT; ENZYME ACTIVITY; HUMAN; PHARMACOGENETICS; RACE DIFFERENCE; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; SYSTEMATIC REVIEW;

ASIAN CONTINENTAL ANCESTRY GROUP; EUROPEAN CONTINENTAL ANCESTRY GROUP; FAR EAST; HUMANS; PHARMACEUTICAL PREPARATIONS; POLYMORPHISM, GENETIC; VARIATION (GENETICS);

EID: 4444268163     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1177/0091270004268128     Document Type: Review

References (390)

1. Dollery CT, Fraser HS, Mucklow JC, et al. Contribution of environmental factors to variability in human drug metabolism. Drug Metab Rev. 1979;9(2):207-220.
2. Fraser HS, Mucklow JC, Bulpitt CJ, et al. Environmental factors affecting antipyrine metabolism in London factory and office workers. Br J Clin Pharmacol. 1979;7(3):237-243.
3. Desai NK, Sheth UK, Mucklow JC, et al. Antipyrine clearance in Indian villagers. Br J Clin Pharmacol. 1980;9(4):387-394.
4. Kalow W, Bertilsson L. Interethnic factors affecting drug response. Adv Drug Res. 1994;25:1-53.
5. Thomas JA. Drug-nutrient interactions. Nutr. Rev. 1995;53(10):271-282.
6. Smith MW, Mendoza RP. Ethnicity and pharmacogenetics. Mt Sinai J Med. 1996;63(5-6):285-290.
7. Tschanz C, Stargel WW, Thomas JA. Interactions between drugs and nutrients. Adv Pharmacol. 1996;35:1-26.
8. Frackiewicz EJ, Sramek J, Herrera JM, et al. Ethnicity and antipsychotic response. Ann Pharmacother. 1997;31(11):1360-1369.
9. Fleisher D, Li C, Zhou Y, et al. Drug, meal and formulation interactions influencing drug absorption after oral administration. Clin Pharmacokinet. 1999;36(3):233-254.
10. Kalow W. Interethnic differences in drug response. In: Kalow W, Meyer UA, Tyndale RF, eds. Pharmacogenomics. New York: Marcel Dekker, 2001;109-134.
11. Burroughs VJ, Maxey RW, Levy RA. Racial and ethnic differences in response to medicines: towards individualized pharmaceutical treatment. J Natl Med Assoc. 2002;94(10, Suppl.):1-26.
12. Liu GT. Effects of some compounds isolated from the Chinese medicinal herbs on hepatic microsomal cytochrome P-450 and their potential biological consequences. Drug Metab Rev. 1991;23(3-4):439-465.
13. Wilkinson GR. The effects of diet, aging and disease-states on presystemic elimination and oral drug bioavailability in humans. Adv Drug Deliv Rev. 1997;27(2-3):129-159.
14. Ingelman-Sundberg M. Pharmacogenetics: an opportunity for a safer and more efficient pharmacotherapy. J Intern Med. 2001;250(3):186-200.
15. Zühlsdorf MT. Relevance of pheno- and genotyping in clinical drug development. Int J Clin Pharmacol Ther. 1998;36(11):607-612.
16. Evans WE, Relling MV. Pharmacogenomics: translating functional genomics into rational therapeutics. Science. 1999;286(5439):487-491.
17. Evans WE, Johnson JA. Pharmacogenomics: the inherited basis for interindividual differences in drug response. Annu Rev. Genomics Hum Genet. 2001;2:9-39.
18. Ingelman-Sundberg M. Implications of polymorphic cytochrome P450-dependent drug metabolism for drug development. Drug Metab Dispos. 2001;29(4):570-573.
19. McLeod HL, Evans WE. Pharmacogenomics: unlocking the human genome for better drug therapy. Annu Rev Pharmacol Toxicol. 2001;41:101-121.
20. Meyer UA. Pharmacogenetics (clinical viewpoints). In: Kalow W, Meyer UA, Tyndale RF, eds. Pharmacogenomics. New York: Marcel Dekker, 2001;135-150.
21. Evans WE, McLeod HL. Pharmacogenomics: drug disposition, drug targets, and side effects. N Engl J Med. 2003;348(6):538-549.
22. Ingelman-Sundberg M, Oscarson M, McLellan RA. Polymorphic human cytochrome P450 enzymes: an opportunity for individualized drug treatment. Trends Pharmacol Sci. 1999;20(8):342-349.
23. Nebert DW, Dieter MZ. The evolution of drug metabolism. Pharmacology. 2000;61(3):124-135.
24. Wolf CR, Smith G, Smith RL. Science, medicine, and the future: pharmacogenetics. Br Med J. 2000;320(7240):987-990.
25. Editorials: genes, drugs and race. Nat Genet. 2001;29(3):239-240.
26. Ma MK, Woo MH, McLeod HL. Genetic basis of drug metabolism. Am J Health Syst Pharm. 2002;59(21):2061-2069.
27. Weinshilboum R. Inheritance and drug response. N Engl J Med. 2003;348(6):529-537.
28. Committee ICoHS. Guidance on ethnic factors in the acceptability of foreign clinical data; availability. Fed Regist. 1998;63(111):31790-31796.
29. Lou YC. Differences in drug metabolism polymorphism between Orientals and Caucasians. Drug Metab Rev. 1990;22(5):451-475.
30. Kalow W. Interethnic variation of drug metabolism. Trends Pharmacol Sci. 1991;12(3):102-107.
31. Wood AJJ, Zhou HH. Ethnic differences in drug disposition and responsiveness. Clin Pharmacokinet. 1991;20(5):350-373.
32. Bertilsson L. Geographical/interracial differences in polymorphic drug oxidation (current state of knowledge of cytochrome P450 (CYP) 2D6 and 2C19). Clin Pharmacokinet. 1995;29(3):192-209.
33. Daly AK. Molecular basis of polymorphic drug metabolism. J Mol Med. 1995;73(11):539-553.
34. Lin KM, Anderson D, Poland RE. Ethnicity and psychopharmacology (bridging the gap). Psychiatr Clin North Am. 1995;18(3):635-647.
35. Wood AJJ. Ethnic differences in drug disposition and response. Ther Drug Monit. 1998;20(5):525-526.
36. Evans DAP, Mcleod HL, Pritchard S, et al. Interethnic variability in human drug responses. Drug Metab Dispos. 2001;29(4):606-610.
37. Lin KM, Smith MW, Ortiz V. Culture and psychopharmacology. Psychiatr Clin North Am. 2001;24(3):523-538.
38. Wood AJJ. Racial differences in the response to drugs: pointers to genetic differences. N Engl J Med. 2001;344(18):1393-1395.
39. Xie HG, Kim RB, Wood AJJ, et al. Molecular basis of ethnic differences in drug disposition and response. Annu Rev Pharmacol Toxicol. 2001;41:815-850.
40. Bjornsson T, Wagner JA, Donahue SR, et al. A review and assessment of potential sources of ethnic differences in drug responsiveness. J Clin Pharmacol. 2003;43(9):943-967.
41. Fojo AT. Multidrug resistance. Adv Intern Med. 1991;36:195-218.
42. Lown KS, Mayo RR, Leichtman AB, et al. Role of intestinal P-glycoprotein (mdr1) in interpatient variation in the oral bioavailability of cyclosporine. Clin Pharmacol Ther. 1997;62(3):248-260.
43. Kim RB, Fromm MF, Wandel C, et al. The drug transporter P-glycoprotein limits oral absorption and brain entry of HTV-1 protease inhibitors. J Clin Invest. 1998;101(2):289-294.
44. Rao W, Dahlheimer JL, Bardgett ME, et al. Choroid plexus epithelial expression of MDR1 P glycoprotein and multidrug resistance-associated protein contribute to the blood-cerebrospinal-fluid drug-permeability barrier. Proc Natl Acad Sci USA. 1999;96(7):3900-3905.
45. Rodriguez I, Abernethy DR, Woosley RL. P-glycoprotein in clinical cardiology. Circulation. 1999;99(4):472-474.
46. Yu DK. The contribution of P-glycoprotein to pharmacokinetic drug-drug interactions. J Clin Pharmacol. 1999;39(12):1203-1211.
47. Choo EF, Leake B, Wandel C, et al. Pharmacological inhibition of P-glycoprotein transport enhances the distribution of HTV-1 protease inhibitors into brain and testes. Drug Metab Dispos. 2000;28(6):655-660.
48. Fromm MF. P-glycoprotein: a defense mechanism limiting oral bioavailability and CNS accumulation of drugs. Int J Clin Pharmacol Ther. 2000;38(2):69-74.
49. Fromm MF. The influence of MDR1 polymorphisms on P-glycoprotein expression and function in human. Adv Drug Deliv Rev. 2002;54(10):1295-1310.
50. Kim RB. Transporters and xenobiotic disposition. Toxicology. 2002;181-182:291-297.
51. Hoffmeyer S, von Richter BO, Arnold HP, et al. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci USA. 2000;97(7):3473-3478.
52. Cascorbi I, Gerloff T, Johne A, et al. Frequency of single nucleotide polymorphisms in the P-glycoprotein drug transporter MDR1 gene in white subjects. Clin Pharmacol Ther. 2001;69(3):169-174.
53. Kim RB, Leake BF, Choo EF, et al. Identification of functionally variant MDR1 alleles among European Americans and African Americans. Clin Pharmacol Ther. 2001;70(2):189-199.
54. Sakaeda T, Nakamura T, Horinouchi M, et al. MDR1 genotype-related pharmacokinetics of digoxin after single oral administration in healthy Japanese subjects. Pharm Res. 2001;18(10):1400-1404.
55. Schaeffeler E, Eichelbaum M, Brinkmann U, et al. Frequency of C3435T polymorphism of MDR1 gene in African people. Lancet. 2001;358(9279):383-384.
56. Fellay J, Marzolini C, Meaden ER, et al. Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study. Lancet. 2002;359(9300):30- 36.
57. Kurata Y, Ieiri I, Kimura M, et al. Role of human MDR1 gene polymorphism in bioavailability and interaction of digoxin, a substrate of P-glycoprotein. Clin Pharmacol Ther. 2002;72(2):209-219.
58. Chowbay B, Cumaraswamy S, Cheung YB, et al. Genetic polymorphisms in MDR1 and CYP3A4 genes in Asians and the influence of MDR1 haplotypes on cyclosporin disposition in heart transplant recipients. Pharmacogenetics. 2003;13(2):89-95.
59. Yates CR, Zhang W, Song P, et al. The effect of CYP3A5 and MDR1 polymorphic expression on cyclosporine oral disposition in renal transplant patients. J Clin Pharmacol. 2003;43(6):555-564.
60. Kolars JC, Awni WM, Merion RM, et al. First-pass metabolism of cyclosporin by the gut. Lancet. 1991;338(8781):1488-1490.
61. Hebert MF, Roberts JP, Prueksaritanont T, et al. Bioavailability of cyclosporine with concomitant rifampin administration is markedly less than predicted by hepatic enzyme induction. Clin Pharmacol Ther. 1992;52(5):453-457.
62. Kolars JC, Schmiedlin-Ren P, Schuetz JD, et al. Identification of rifampin-inducible P450IIIA4 (CYP3A4) in human bowel enterocytes. J Clin Invest. 1992;90(5):1871-1878.
63. Gomez DY, Wacher VJ, Tomlanovich SJ, et al. The effects of ketoconazole on the intestinal metabolism and bioavailability of cyclosporine. Clin Pharmacol Ther. 1995;58(1):15-19.
64. Wu CY, Benet LZ, Hebert MF, et al. Differentiation of absorption and first-pass gut and hepatic metabolism in humans: studies with cyclosporine. Clin Pharmacol Ther. 1995;58(5):492-497.
65. Lennernaus H. Animal perfusion studies. In: Dressman JB, Lennernaus H, eds. Oral Drug Absorption. New York: Marcel Dekker, 2000;86-90.
66. Goto M, Masuda S, Saito H, et al. C3435T polymorphism in the MDR1 gene affects the enterocyte expression level of CYP3A4 rather than Pgp in recipients of living-donor liver transplantation. Pharmacogenetics. 2002;12(6):451-457.
67. Schuetz EG, Beck WT, Schuetz JD. Modulators and substrates of P-glycoprotein and cytochrome P4503A coordinately up-regulate these proteins in human colon carcinoma cells. Mol Pharm. 1996;49(2):311-318.
68. Wacher VJ, Silverman JA, Zhang Y, et al. Role of P-glycoprotein and cytochrome P450 3A in limiting oral absorption of peptides and peptidomimetics. J Pharm Sci. 1998;87(11):1322-1330.
69. Kim RB, Wandel C, Leake B, et al. Interrelationship between substrates and inhibitors of human CYP3A and P-glycoprotein. Pharm Res. 1999;16(3):408-414.
70. Bailey DG, Spence JD, Munoz C, et al. Interaction of citrus juices with felodipine and nifedipine. Lancet. 1991;337(8736):268-269.
71. Ducharme MP, Warbasse LH, Edwards DJ. Disposition of intravenous and oral cyclosporine after administration with grapefruit juice. Clin Pharmacol Ther. 1995;57(5):485-491.
72. Kupferschmidt HHT, Ha HR, Ziegler WH, et al. Interaction between grapefruit juice and midazolam in humans. Clin Pharmacol Ther. 1995;58(1):20-28.
73. Hukkinen SK, Varhe A, Olkkola KT, et al. Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice. Clin Pharmacol Ther. 1995;58(2):127-131.
74. Yee GC, Stanley DL, Pessa LJ, et al. Effect of grapefruit juice on blood cyclosporin concentration. Lancet. 1995;345(8955):955-956.
75. Lown KS, Bailey DG, Fontana RJ, et al. Grapefruit juice increases felodipine oral availability in humans by decreasing intestinal CYP3A protein expression. J Clin Invest. 1997;99(10):2545-2553.
76. Rau SE, Bend JR, Arnold MO, et al. Grapefruit juice-terfenadine single-dose interaction: magnitude, mechanism, and relevance. Clin Pharmacol Ther. 1997;61(4):401-409.
77. Kupferschmidt HHT, Fattinger KE, Ha HR, et al. Grapefruit juice enhances the bioavailability of the HIV protease inhibitor saquinavir in man. Br J Clin Pharmacol. 1998;45(4):355-359.
78. Bailey DG, Malcolm J, Arnold O, et al. Grapefruit juice-drug interactions. Br J Clin Pharmacol. 1998;46(2):101-110.
79. Kantola T, Kivistö KT, Neuvonen PJ. Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid. Clin Pharmacol Ther. 1998;64(4):397-402.
80. Lilja JJ, Kivistö KT, Neuvonen PJ. Grapefruit juice-simvastatin interaction: effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors. Clin Pharmacol Ther. 1998;64(5):477-483.
81. Lilja JJ, Kivistö KT, Backman JT, et al. Grapefruit juice substantially increases plasma concentrations of buspirone. Clin Pharmacol Ther. 1998;64(6):655-660.
82. Edwards DJ, Fitzsimmons ME, Schuetz EG, et al. 6′,7′- Dihydroxybergamottin in grapefruit juice and Seville orange juice: effects on cyclosporine disposition, enterocyte CYP3A4, and P-glycoprotein. Clin Pharmacol Ther. 1999;65(3):237-244.
83. Evans AM. Influence of dietary components on the gastrointestinal metabolism and transport of drugs. Ther Drug Monit. 2000;22(1):131-136.
84. Kane GC, Lipsky JJ. Drug-grapefruit juice interactions. Mayo Clin Proc. 2000;75(9):933-942.
85. Libersa CC, Brique SA, Motte KB, et al. Dramatic inhibition of amiodarone metabolism induced by grapefruit juice. Br J Clin Pharmacol. 2000;49(4):373-378.
86. Desta Z, Kivistö KT, Lilja JJ; et al. Stereoselective pharmacokinetics of cisapride in healthy volunteers and the effect of repeated administration of grapefruit juice. Br J Clin Pharmacol. 2001;52(4):399-407.
87. Lee M, Min DI, Ku YM, et al. Effect of grapefruit juice on pharmacokinetics of microemulsion cyclosporine in African American subjects compared with Caucasian subjects: does ethnic difference matter? J Clin Pharmacol. 2001;41(3):317-323.
88. Spahn-Langguth H, Langguth P. Grapefruit juice enhances intestinal absorption of the P-glycoprotein substrate talinolol. Eur J Pharm Sci. 2001;12(4):361-367.
89. Wagner D, Spahn-Langguth H, Hanafy A, et al. Intestinal drug efflux: formulation and food effects. Adv Drug Deliv Rev. 2001;50(Suppl. 1):S13-S31.
90. Di Marco MP, Edwards DJ, Wainer IW, et al. The effect of grape-fruit juice and Seville orange juice on the pharmacokinetics of dextromethorphan: the role of gut CYP3A and P-glycoprotein. Life Sci. 2002;71(10):1149-1160.
91. Fuhr U, Müller-Peltzer H, Kern R, et al. Effects of grapefruit juice and smoking on verapamil concentrations in steady state. Eur J Clin Pharmacol. 2002;58(1):45-53.
92. Bailey DG, Dresser GK, Bend JR. Bergamottin, lime juice, and red wine as inhibitors of cytochrome P450 3A4 activity: comparison with grapefruit juice. Clin Pharmacol Ther. 2003;73(6):529-537.
93. Greenblatt DJ, von Moltke LL, Harmatz JS, et al. Time course of recovery of cytochrome P450 3A function after single doses of grape-fruit juice. Clin Pharmacol Ther. 2003;74(2):121-129.
94. Johnson JA. Influence of race or ethnicity on pharmacokinetics of drugs. J Pharm Sci. 1997;86(12):1328-1333.
95. Johnson JA. Predictability of the effects of race or ethnicity oh pharmacokinetics of drugs. Int J Clin Pharmacol Ther. 2000;38(2):53-60.
96. Ameyaw MM, Regateiro F, Li T, et al. MDR1 pharmacogenetics: frequency of the C3435T mutation in exon 26 is significantly influenced by ethnicity. Pharmacogenetics. 2001;11(3):217-221.
97. Chelule PK, Gordon M, Palanee T, et al. MDR1 and CYP3A4 polymorphisms among African, Indian, and white populations in KwaZulu-Natal, South Africa. Clin Pharmacol Ther. 2003;74(2):195-196.
98. Ito S, Ieiri I, Tanabe M, et al. Polymorphism of the ABC transporter genes, MDR1, MPR1 and MRP2/cMOAT, in healthy Japanese subjects. Pharmacogenetics. 2001;11(2):175-184.
99. Balram C, Sharma A, Sivathasan C, et al. Frequency of C3435T single nucleotide MDR1 genetic polymorphism in an Asian population: phenotypic-genotypic correlates. Br J Clin Pharmacol. 2003;56(1):78-83.
100. Lindholm A, Welsh M, Alton C, et al. Demographic factors influencing cyclosporine pharmacokinetic parameters in patients with uremia: racial differences in bioavailability. Clin Pharmacol Ther. 1992;52(4):359-371.
101. Abrams SA, O'Brien KO, Liang LK, et al. Differences in calcium absorption and kinetics between black and white girls aged 5-16 years. J Bone Miner Res. 1995;10(5):829-833.
102. Andrews PA, Sen M, Chang RWS. Racial variation in dosage requirements of tacrolimus. Lancet. 1996;348(9039):1446.
103. Min DI, Lee M, Ku YM, et al. Gender-dependent racial difference in disposition of cyclosporine among healthy African American and white volunteers. Clin Pharmacol Ther. 2000;68(5):478-486.
104. Mancinelli LM, Frassetto L, Floren LC, et al. The pharmacokinetics and metabolic disposition of tacrolimus: a comparison across ethnic group. Clin Pharmacol Ther. 2001;69(1):24-31.
105. Hervé F, Urien S, Albengres E, et al. Drug binding in plasma (a summary of recent trends in the study of drug and hormone binding). Clin Pharmacokinet. 1994;26(1):44-58.
106. Johnson JA, Livingston TN. Differences between blacks and whites in plasma protein binding of drugs. Eur J Clin Pharmacol. 1997;51(6):485-488.
107. Zhou HH, Adedoyin A, Wilkinson GR. Differences in plasma binding of drugs between Caucasians and Chinese subjects. Clin Pharmacol Ther. 1990;48(1):10-17.
108. Kremer JMH, Wilting J, Janssen LHM. Drug binding to human alpha-1-acid glycoprotein in health and disease. Pharmacol Rev. 1988;40(1):1-47.
109. 1- acid glycoprotein. Br J Clin Pharmacol. 1993;36(3):241-249.
110. Zhou HH, Koshakji RP, Silberstein DJ, et al. Racial differences in drug response (altered sensitivity to and clearance of propranolol in men of Chinese descent as compared with American whites). N Engl J Med. 1989;320(9):565-570.
111. Spector R, Choudhury K, Chiang CK, et al. Diphenhydramine in Orientals and Caucasians. Clin Pharmacol Ther. 1980;28(2):229-234.
112. Fleishaker JC. Clinical pharmacokinetics of reboxetine, a selective norepinephrine reuptake inhibitor for the treatment of patients with depression. Clin Pharmacokinet. 2000;39(6):413-427.
113. Edwards DM, Pellizzoni C, Breuel HP, et al. Pharmacokinetics of reboxetine in healthy volunteers: single oral doses, linearity and plasma protein binding. Biopharm Drug Dispos. 1995;16(6):443-460.
114. Hendershot PE, Fleishaker JC, Lin KM, et al. Pharmacokinetics of reboxetine in healthy volunteers with different ethnic descents. Psychopharmacology. 2001;155(2):148-153.
115. Meyer UA. Genotype or phenotype: the definition of a pharmacogenetic polymorphism. Pharmacogenetics. 1991;1(1):66-67.
116. Rendic S, Di Carlo FJ. Human cytochrome P450 enzymes: a status report summarizing their reactions, substrates, inducers, and inhibitors. Drug Metab Rev. 1997;29(1-2):413-580.
117. Lewis P, Vaddadi KS. Ethnic differences in drug response. Postgrad Med J. 1980;56(Suppl. 1):46-49.
118. Lin KM, Poland RE, Smith MW, et al. Pharmacokinetics and other related factors affecting psychotropic responses in Asians. Psychopharmacol Bull. 1991;27(4):427-439.
119. Kroemer HK, Eichelbaum M. "It's the gene, stupid": molecular basis and clinical consequences of genetic cytochrome P450 2D6 polymorphism. Life Sci 1995;56(26):2285-2298.
120. Fromm MF, Kroemer HK, Eichelbaum M. Impact of P450 genetic polymorphism on the first-pass extraction of cardiovascular and neuroactive drugs. Adv Drug Deliv Rev. 1997;27(2-3):171-199.
121. Martínez C, Agúndez JAG, Gervasini G, et al. Tryptamine: a possible endogenous substrate for CYP2D6. Pharmacogenetics. 1997;7(2):85-93.
122. Kawanishi Y, Tachikawa H, Suzuki T. Pharmacogenomics and schizophrenia. Eur J Pharmacol. 2000;410(2-3):227-241.
123. Lin KM. Biological differences in depression and anxiety across races and ethnic groups. J Clin Psychiatry. 2001;62(Suppl. 13):13-19.
124. Bertilsson L, Dahl ML, Dalén P, et al. Molecular genetics of CYP2D6: clinical relevance with focus on psychotropic drugs. Br J Clin Pharmacol. 2002;53(2):111-122.
125. Idle JR, Corchero J, Gonzalez FJ. Medical implications of HGP's sequence of chromosome 22. Lancet. 2000;355(9200):319.
126. Oscarson M, Ingelman-Sundberg M, Daly AK, et al. Home page of the human cytochrome P450 (CYP) allele nomenclature committee. Retrieved January 30, 2004, from www.imm.ki.se/CYPalleles/
127. Meyer UA, Zanger UM. Molecular mechanisms of genetic polymorphisms of drug metabolism. Annu Rev Pharmacol Toxicol. 1997:37:269-296.
128. Bertilsson L, Dahl ML, Sjöqvist F, et al. Molecular basis for rational megaprescribing in ultrarapid hydroxylators of debrisoquine. Lancet. 1993;341(8836):63.
129. Johansson I, Lundqvist E, Bertilsson L, et al. Inherited amplication of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine. Proc Natl Acad Sci USA. 1993;90(24):11825-11829.
130. Dahl ML, Johansson I, Bertilsson L, et al. Ultrarapid hydroxylation of debrisoquine in a Swedish population: analysis of the molecular genetic basis. J Pharmacol Exp Ther. 1995;274(1):516-520.
131. Dahl ML, Johansson I, Palmertz MP, et al. Analysis of the CYP2D6 gene in relation to debrisoquin and desipramine hydroxylation in a Swedish population. Clin Pharmacol Ther. 1992;51(1):12-17.
132. Dalén P, Dahl ML, Ruiz MLB, et al. 10-Hydroxylation of nortriptyline in white persons 0, 1, 2, 3, and 13 functional CYP2D6 genes. Clin Pharmacol Ther. 1998;63(4):444-452.
133. Yokota H, Tamura S, Furuya H, et al. Evidence for a new variant CYP2D6 allele CYP2D6J in a Japanese population associated with lower in vivo rates of sparteine metabolism. Pharmacogenetics. 1993;3(5):256-263.
134. Johansson I, Oscarson M, Yue QY, et al. Genetic analysis of the Chinese cytochrome P4502D locus: characterization of variant CYP2D6 genes present in subjects with diminished capacity for debrisoquine hydroxylation. Mol Pharmacol. 1994;46(3):452-459.
135. Lai ML, Wang SL, Lai MD, et al. Propranolol disposition in Chinese subjects of different CYP2D6 genotypes. Clin Pharmacol Ther. 1995;58(3):264-268.
136. Mihara K, Otani K, Tybring G, et al. The CYP2D6 genotype and plasma concentrations of mianserin enantiomers in relation to therapeutic response to mianserin in depressed Japanese patients. J Clin Pyschopharmacol. 1997;17(6):467-471.
137. Sachse C, Brockmöller J, Bauer S, et al. Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences. Am J Hum Genetic. 1997;60(2):284-295.
138. Fukuda T, Yamamoto I, Nishida Y, et al. Effect of the CYP2D6*10 genotype on venlafaxine pharmacokinetics in healthy adult volunteers. Br J Clin Pharmacol. 1999;47(4):450-453.
139. Tateishi T, Chida M, Ariyoshi N, et al. Analysis of the CYP2D6 gene in relation to dextromethorphan O-demethylation capacity in a Japanese population. Clin Pharmacol Ther. 1999;65(5):570-575.
140. Fukuda T, Nishida Y, Zhou Q, et al. The impact of the CYP2D6 and CYP2C19 genotypes on venlafaxine pharmacokinetics in a Japanese population. Eur J Clin Pharmacol. 2000;56(2):175-180.
141. Kubota T, Yamaura Y, Ohkawa N, et al. Frequencies of CYP2D6 mutant alleles in a normal Japanese population and metabolic activity of dextromethorphan O-demethylation in different CYP2D6 genotypes. Br J Clin Pharmacol. 2000;50(1):31-34.
142. Roh H, Kim C, Chung W, et al. Risperidone metabolism in relation to CYP2D6*10 allele in Korean schizophrenic patients. Eur J Clin Pharmacol. 2001;57(9):671-675.
143. Kim MK, Cho JY, Lim HS, et al. Effect of the CYP2D6 genotype on the pharmacokinetics of tropisetron in healthy Korean subjects. Eur J Clin Pharmacol. 2003;59(2):111-116.
144. Shimada T, Tsumura F, Yamazaki H, et al. Characterization of (±)-bufuralol hydroxylation activities in liver microsomes of Japanese and Caucasian subjects genotyped for CYP2D6. Pharmacogenetics. 2001;11(2):143-156.
145. Huang J, Chuang SK, Cheng CL, et al. Pharmacokinetics of metoprolol enantiomers in Chinese subjects of major CYP2D6 genotypes. Clin Pharmacol Ther. 1999;65(4):402-407.
146. Yoon YR, Cha IJ, Shon JH, et al. Relationship of paroxetine disposition to metoprolol metabolic ratio and CYP2D6* 10 genotype of Korean subjects. Clin Pharmacol Ther. 2000;67(5):567-576.
147. Lessard E, Yessine MA, Hamelin BA, et al. Influence of CYP2D6 activity on the disposition and cardiovascular toxicity of the antidepressant agent venlafaxine in humans. Pharmacokinetics. 1999;9(4):435-443.
148. Dahl ML, Bertilsson L, Nordin C. Steady-state plasma levels of nortriptyline and its 10-hydroxy metabolite: relationship to the CYP2D6 genotype. Psychopharmacology. 1996;123(4):315-319.
149. Yue QY, Zhong ZH, Tybring G, et al. Pharmacokinetics of nortriptyline and its 10-hydroxy metabolite in Chinese subjects of different CYP2D6 genotypes. Clin Pharmacol Ther. 1998;64(4):384-390.
150. Morita S, Shimoda K, Someya T, et al. Steady-state plasma levels of nortriptyline and its hydroxylated metabolites in Japanese patients: impact of CYP2D6 genotype on the hydroxylation of nortriptyline. J Clin Psychopharmacol. 2000;20(2):141-149.
151. Dalén P, Dahl ML, Eichelbaum M, et al. Disposition of debrisoquine in Caucasians with different CYP2D6-genotypes including those with multiple genes. Pharmacogenetics. 1999;9(6):697-706.
152. Kishimoto A, Hollister L. Nortriptyline kinetics in Japanese and Americans. J Clin Psychopharmacol. 1984;4(3):171-172.
153. Tsang MW, Shader RI, Greenblatt DJ. Metabolism of haloperidol: clinical implications and unanswered questions. J Clin Psychopharmacol. 1994;14(3):159-162.
154. Lerena A, Aim C, Dahl ML, et al. Haloperidol disposition is dependent on debrisoquine hydroxylation phenotype. Ther Drug Monit. 1992;14(2):92-97.
155. Lerena A, Dahl ML, Ekqvist B, et al. Haloperidol disposition is dependent on the debrisoquine hydroxylation phenotype: increased plasma levels of the reduced metabolite in poor metabolizers. Ther Drug Monit. 1992;14(3):261-264.
156. Suzuki A, Otani K, Mihara K, et al. Effects of the CYP2D6 genotype on the steady-state plasma concentrations of haloperidol and reduced haloperidol in Japanese schizophrenic patients. Pharmacokinetics. 1997;7(5):415-418.
157. Mihara K, Suzuki A, Kondo T, et al. Effects of the CYP2D6*10 allele on the steady-state plasma concentrations of haloperidol and reduced haloperidol in Japanese patients with schizophrenia. Clin Pharmacol Ther. 1999;65(3):291-294.
158. Roh HK, Chung JY, Oh DY, et al. Plasma concentrations of haloperidol are related to CYP2D6 genotype at low, but not high doses of haloperidol in Korean schizophrenic patients. Br J Clin Pharmacol. 2001;52(3):265-271.
159. Lin KM, Finder E. Neuroleptic dosage for Asians. Am J Psychiatry. 1983;140(4):490-491.
160. Chang WH, Chen TY, Lee CF, et al. Low plasma reduced haloperidol/ haloperidol ratios in Chinese patients. Biol Psychiatry. 1987;22(11):1406-1408.
161. Collazo Y, Tam R, Sramek J, et al. Neuroleptic dosing in Hispanic and Asian inpatients with schizophrenia. Mt Sinai J Med. 1996;63(5-6):310-313.
162. Lin KM, Poland RE, Nuccio I, et al. A longitudinal assessment of haloperidol doses and serum concentrations in Asian and Caucasian schizophrenic patients. Am J Psychiatry. 1989;146(10):1307-1311.
163. Pi EH, Wang AL, Gray GE. Asian/non-Asian transcultural tricyclic antidepressant psychopharmacology: a review. Prog Neuro-Psychopharmacol. 1993;17(5):691-702.
164. Ruiz S, Chu P, Sramek J, et al. Neuroleptic dosing in Asian and Hispanic outpatients with schizophrenia. Mt Sinai J Med. 1996;63(5-6):306-309.
165. Lin KM, Poland RE, Lau JK, et al. Haloperidol and prolactin concentrations in Asians and Caucasians. J Clin Psychopharmacol. 1988;8(3):195-201.
166. Zhang-Wong J, Beiser M, Zipursky R, et al. An investigation of ethnic and gender differences in the pharmacodynamics of haloperidol. Psychiatry Res. 1998;81(3):333-339.
167. Yue QY, Svensson JO, Aim C, et al. Interindividual and interethnic differences in the demethylation and glucuronidation of codeine. Br J Clin Pharmacol. 1989;28(6):629-637.
168. Yue QY, Hasselström J, Svensson JO, et al. Pharmacokinetics of codeine and its metabolites in Caucasian healthy volunteers: comparisons between extensive and poor hydroxylators of debrisiquine. Br J Clin Pharmacol. 1991;31(6):635-642.
169. Tseng CY, Wang SL, Lai MD, et al. Formation of morphine from codeine in Chinese subjects of different CYP2D6 genotypes. Clin Pharmacol Ther. 1996;60(2):177-182.
170. Yue QY, Svensson JO, Sjöqvist F, et al. A comparison of the pharmacokinetics of codeine and its metabolites in healthy Chinese and Caucasian extensive hydroxylators of debrisoquine. Br J Clin Pharmacol. 1991;31(6):643-647.
171. Caraco Y, Sheller J, Wood AJJ. Impact of ethnic origin and quinidine coadministration on codeine's disposition and pharmacodynamic effects. J Pharmacol Exp Ther. 1999;290(1):413-422.
172. Yue QY, Svensson JO, Säwe J, et al. Codeine metabolism in three Oriental populations: a pilot study in Chinese, Japanese and Koreans. Pharmacogenetics. 1995;5(3):173-177.
173. Sohn D, Shin S, Park C, et al. Metoprolol oxidation polymorphism in a Korean population: comparison with native Japanese and Chinese populations. Br J Clin Pharmacol. 1991;32(4):504-507.
174. Kalow W, Otton SV, Kadar D, et al. Ethnic difference in drug metabolism: debrisoquine 4-hydroxyration in Caucasians and Orientals. Can J Physiol Pharmacol. 1980;58(9):1142-1144.
175. Rudorfer MV, Lane EA, Chang WH, et al. Desipramine pharmacokinetics in Chinese and Caucasian volunteers. Br J Clin Pharmacol. 1984;17(4):433-440.
176. Brøsen K, Gram LF. First-pass metabolism of imipramine and desipramine: impact of the sparteine oxidation phenotype. Clin Pharmacol Ther. 1988;43(4):400-406.
177. Nielsen KK, Broensen K, Hansen MGJ, et al. Single-dose kinetics of clomipramine: relationship to the sparteine and S-mephenytoin oxidation polymorphisms. Clin Pharmacol Ther. 1994;55(5):518-527.
178. Shimoda K, Jerling M, Böttiger Y, et al. Pronounced differences in the disposition of clomipramine between Japanese and Swedish patients. J Clin Psychopharmacol. 1999;19(5):393-400.
179. Wedlund PJ, Aslanian WS, McAllister CB, et al. Mephenytoin hydroxylation deficiency in Caucasians: frequency of a new oxidative drug metabolism polymorphism. Clin Pharmacol Ther. 1984;36(6):773-780.
180. Nakamura K, Goto F, Ray WA, et al. Interethnic differences in genetic polymorphism of debrisoquin and mephenytoin hydroxylation between Japanese and Caucasian populations. Clin Pharmacol Ther. 1985;38(4):402-408.
181. Lou YC, Ying L, Bertilsson L, et al. Low frequency of slow debrisoquine hydroxylation in a native Chinese population. Lancet. 1987;330(8563):852-853.
182. Alván G, Bechtel P, Iselius L, et al. Hydroxylation polymorphisms of debrisoquine and mephenytoin in European populations. Eur J Clin Pharmacol. 1990;39(6):533-537.
183. Bertilsson L, Lou YQ, Du YL, et al. Pronounced differences between native Chinese and Swedish populations in the polymorphic hydroxylations of debrisoquin and S-mephenytoin. Clin Pharmacol Ther. 1992;51(4):388-397.
184. Wang SL, Huang J, Lai MD, et al. Molecular basis of genetic variation in debrisoquin hydroxylation in Chinese subjects: polymorphism in RFLP and DNA sequence of CYP2D6. Clin Pharmacol Ther. 1993;53(4):410-418.
185. Gaedigk A. Interethnic differences of drug-metabolizing enzymes. Int J Clin Pharmacol Ther. 2000;38(2):61-68.
186. Johansson I, Yue QY, Dahl ML, et al. Genetic analysis of the interethnic difference between Chinese and Caucasians in the polymorphic metabolism of debrisoquine and codeine. Eur J Clin Pharmacol. 1991;40(6):553-556.
187. Masimirembwa CM, Hasler JA. Genetic polymorphism of drug metabolizing enzymes in African populations: implications for the use of neuroleptics and antidepressants. Brain Res Bull. 1997;44(5):561-571.
188. Wennerholm A, Johansson I, Massele AY, et al. Decreased capacity for debrisoquine metabolism among black Tanzanians: analyses of the CYP2D6 genotype and phenotype. Pharmacogenetics. 1999;9(6):707-714.
189. Amstrong M, Fairbrother K, Idle J, et al. The cytochrome P450 CYP2D6 allelic variant CYP2D6J and related polymorphisms in a European population. Pharmacogenetics. 1994;4(2):73-81.
190. Nishida Y, Fukuda T, Yamamoto I, et al. CYP2D6 genotypes in a Japanese population: low frequencies of CYP2D6 gene duplication but high frequency of CYP2D6*10. Pharmacogenetics. 2000;10(6):567-570.
191. Mitsunaga Y, Kubota T, Ishiguro A, et al. Frequent occurrence of CYP2D6*10 duplication allele in a Japanese population. Mutât Res. 2002;505(1-2):83-85.
192. Agundez JA, Ledesma MC, Ladero JM, et al. Prevalence of CYP2D6 gene duplication and its repercussion on the oxidative phenotype in a white population. Clin Pharmacol Ther. 1995;57(3):265-269.
193. London SJ, Daly AK, Leathart JBS, et al. Genetic polymorphism of CYP2D6 and lung cancer risk in African-American and Caucasians in Los Angeles County. Carcinogenesis. 1997;18(6):1203-1214.
194. Bernal ML, Sinues B, Johansson I, et al. Ten percent of North Spanish individuals carry duplicated or triplicated CYP2D6 genes associated with ultrarapid metabolism of debrisoquine. Pharmacogenetics. 1999;9(5):657-660.
195. Dahl ML, Yue QY, Roh HK, et al. Genetic analysis of the CYP2D locus in relation to debrisoquine hydroxylation capacity in Korean, Japanese and Chinese subjects. Pharmacogenetics. 1995;5(3):159-164.
196. Goldstein JA, de Morais SMF. Biochemistry and molecular biology of the human CYP2C subfamily. Pharmacogenetics. 1994;4(6):285-299.
197. Miners JO, Birkett DJ. Cytochrome P4502C9: an enzyme of major importance in human drug metabolism. Br J Clin Pharmacol. 1998;45(6):525-538.
198. Goldstein JA. Clinical relevance of genetic polymorphisms in the human CYP2C subfamily. Br J Clin Pharmacol. 2001;52(4):349-355.
199. Obach RS, Zhang QY, Dunbar D, et al. Metabolic characterization of the major human small intestinal cytochrome P450s. Drug Metab Dispos. 2001;29(3):347-352.
200. Wilkinson GR, Guengerich FP, Branch RA. Genetic polymorphism of S-mephenytoin hydroxylation. Pharmacol Ther. 1989;43(1):53-76.
201. Bertilsson L, Henthorn TK, Sanz E, et al. Importance of genetic factors in the regulation of diazepam metabolism: relationship to S-mephenytoin, but not debrisoquin, hydroxylation phenotype. Clin Pharmacol Ther. 1989;45(4):348-355.
202. Ward SA, Walle T, Walle K, et al. Propranolol's metabolism is determined by both mephenytoin and debrisoquin hydroxylase activities. Clin Pharmacol Ther. 1989;45(1):72-79.
203. Adedoyin A, Prakash C, O'Shea D, et al. Stereoselective disposition of hexobarbital and its metabolites: relationship to the S-mephenytoin polymorphism in Caucasian and Chinese subjects. Pharmacogenetics. 1994;4(1):27-38.
204. Koyama E, Sohn D, Shin S, et al. Metabolic disposition of imipramine in Oriental subjects: relation to metoprolol α-hydroxylation and S-mephenytoin 4′-hydroxylation phenotypes. J Pharmacol Exp Ther. 1994;271(2):860-867.
205. Andersson T, Holmberg J, Röhss K, et al. Pharmacokinetics and effect on caffeine metabolism of the proton pump inhibitors, omeprazole, lansoprazole, and pantoprazole. Br J Clin Pharmacol. 1998;45(4):369-375.
206. Poolsup N, Po LW, Knight TL. Pharmacogenetics and psychopharmacotherapy. J Clin Pharm Ther. 2000;25(3):197-220.
207. Horai Y, Kimura M, Furuie H, et al. Pharmacodynamic effects and kinetic disposition of rabeprazole in relation to CYP2C19 genotypes. Aliment Pharmacol Ther. 2001;15(6):793-803.
208. Wang JH, Liu ZQ, Wang W, et al. Pharmacokinetics of sertraline in relation to genetic polymorphism of CYP2C19. Clin Pharmacol Ther. 2001;70(1):42-47.
209. Desta Z, Zhao X, Shin J, et al. Clinical significance of the cytochrome P450 2C19 genetic polymorphism. Clin Pharmacokinet. 2002;41(12):913-958.
210. Jiang ZP, Shu YS, Chen XP, et al. The role of CYP2C19 in amitriptyline N-demethylation in Chinese subjects. Eur J Clin Pharmacol. 2002;58(2):109-113.
211. de Morais SMF, Wilkinson GR, Meyer UA, et al. Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese. Mol Pharmacol. 1994;46(4):594-598.
212. de Morais SMF, Goldstein JA, Xie HG, et al. Genetic analysis of the S-mephenytoin polymorphism in a Chinese population. Clin Pharmacol Ther. 1995;58(4):404-411.
213. Balian J, Sukhova N, Harris JW, et al. The hydroxylation of omeprazole correlates with S-mephenytoin metabolism: a population study. Clin Pharmacol Ther. 1995;57(6):662-669.
214. Chang M, Tybring G, Götharson E, et al. Interphenotype differences in disposition and effect on gastrin levels of omeprazole: suitability of omeprazole as a probe for CYP2C19. Br J Clin Pharmacol. 1995;39(5):511-518.
215. m2 in exon 4, in Japanese subjects. Clin Pharmacol Ther. 1996;59(6):647-653.
216. Furuta T, Ohashi K, Kamata T, et al. Effect of genetic differences in omeprazole metabolism on cure rates for Helicobacter pylori infection and peptic ulcer. Ann Intern Med. 1998;129(12):1027-1030.
217. Furuta T, Ohashi K, Kosuge K, et al. CYP2C19 genotype status and effect of omeprazole on intragastric pH in humans. Clin Pharmacol Ther. 1999;65(5):552-561.
218. Andersson T, Regardh CG, Lou YC, et al. Polymorphic hydroxylation of S-mephenytoin and omeprazole metabolism in Caucasian and Chine se subjects. Pharmacogenetics. 1992;2(1):25-31.
219. Caraco Y, Lagerstrom PO, Wood AJJ. Ethnic and genetic determinants of omeprazole disposition and effect. Clin Pharmacol Ther. 1996;60(2):157-167.
220. Ishizaki T, Sohn D, Kobayashi K, et al. Interethnic differences in omeprazole metabolism in the two S-mephenytoin hydroxylation phenotypes studied in Caucasians and Orientals. Ther Drug Monit. 1994;16(2):214-215.
221. Kumara CR, Lauder IJ, Chan M, et al. Differences in diazepam pharmacokinetics in Chinese and white Caucasians: relation to body lipid stores. Eur J Clin Pharmacol. 1987;32(2):211-215.
222. Qin XP, Xie HG, Wang W, et al. Effect of the gene dosage of CYP2C19 on diazepam metabolism in Chinese subjects. Clin Pharmacol Ther. 1999;66(6):642-646.
223. Ghoneim MM, Korttila K, Chiang CK, et al. Diazepam effects and kinetics in Caucasians and Orientals. Clin Pharmacol Ther. 1981;29(6):749-756.
224. Zhang Y, Revirego J, Lou Y, et al. Diazepam metabolism in native Chinese poor and extensive hydroxylators of S-mephenytoin: interethnic differences in comparison with white subjects. Clin Pharmacol Ther. 1990;48(5):496-502.
225. Bertilsson L. Why are diazepam metabolism and polymorphic S-mephenytoin hydroxylation associated with each other in white and Korean populations but not in Chinese populations? Clin Pharmacol Ther. 1992;53(5):608-610.
226. Karam WG, Goldstein JA, Lasker LM, et al. Human CYP2C19 is a major omeprazole 5-hydroxylase, as demonstrated with recombinant cytochrome P450 enzymes. Drug Metab Dispos. 1996;24(10):1081-1087.
227. Äbelö A, Andersson TB, Bredberg U, et al. Stereoselective metabolism by human liver CYP enzymes of a substituted benzimidazole. Drug Metab Dispos. 2000;28(1):58-64.
228. Yamazaki H, Inoue K, Shaw PM, et al. Different contributions of cytochrome P450 2C19 and 3A4 in the oxidation of omeprazole by human liver microsomes: effects of contents of these two forms in individual human samples. J Pharmacol Exp Ther. 1997;283(2):434-442.
229. Kupfer A, Branch RA. Stereoselective mephobarbital hydroxylation cosegregates with mephenytoin hydroxylation. Clin Pharmacol Ther. 1985;38(4):414-418.
230. Knodell RG, Dubey RK, Wilkinson GR, et al. Oxidative metabolism of hexobarbital in human liver: relationship to polymorphic S-mephenytoin 4-hydroxylation. J Pharmacol Exp Ther. 1988;245(3):845-849.
231. Yasumori T, Murayama N, Yamazoe Y, et al. Polymorphism in hydroxylation of mephenytoin and hexobarbital stereoisomers in relation to hepatic P-450 human-2. Clin Pharmacol Ther. 1990;47(3):313-322.
232. Gidal BE, Zupanc ML. Potential pharmacokinetic interaction between felbamate and phenobarbital. Ann Pharmacother. 1994;28(4):455-458.
233. Reidenberg P, Glue P, Banfield CR, et al. Effects of felbamate on the pharmacokinetics of phenobarbital. Clin Pharmacol Ther. 1995;58(3):279-287.
234. Mamiya K, Hadama A, Yukawa E, et al. CYP2C19 polymorphism effect on phenobarbitone: pharmacokinetics in Japanese patients with epilepsy: analysis by population pharmacokinetics. Eur J Clin Pharmacol. 2000;55(11-12):821-825.
235. Hamada A, Ieiri I, Morita T, et al. P-hydroxylation of phenobarbital: relationship to (S)-mephenytoin hydroxylation (CYP2C19) polymorphism. Ther Drug Monit. 2001;23(2):115-118.
236. Kobayashi K, Kogo M, Tani M, et al. Role of CYP2C19 in stereoselective hydroxylation of mephobarbital by human liver microsomes. Drug Metab Dispos. 2001;29(1):36-40.
237. Jurima M, Inaba T, Kadar D, et al. Genetic polymorphism of mephenytoin p(4′)-hydroxylation: difference between Orientals and Caucasians. Br J Clin Pharmacol. 1985;19(4):483-487.
238. Horai Y, Nakano M, Ishizaki T, et al. Metoprolol and mephenytoin oxidation polymorphisms in Far Eastern Oriental subjects: Japanese versus mainland Chinese. Clin Pharmacol Ther. 1989;46(2):198-207.
239. Sohn D, Kusaka M, Ishizaki T, et al. Incidence of S-mephenytoin hydroxylation deficiency in a Korean population and the interphenotypic differences in diazepam pharmacokinetics. Clin Pharmacol Ther. 1992;52(2):160-169.
240. Xie HG, Stein CM, Kim RB, et al. Allelic, genotypic and phenotypic distributions of S-mephenytoin 4′-hydroxylase (CYP2C19) in healthy Caucasian populations of European descent throughout the world. Pharmacogenetics. 1999;9(5):539-549.
241. Xie HG. Genetic variations of S-mephenytoin 4′-hydroxylase (CYP2C19) in the Chinese population. Life Sci. 2000;66(14):PL 175-181.
242. Goldstein JA, Ishzaki T, Chiba K, et al. Frequencies of the defective CYP2C19 alleles responsible for the mephenytoin poor metabolizer phenotype in various Oriental, Caucasian, Saudi Arabian and American black populations. Pharmacogenetics. 1997;7(1):59-64.
243. Inoue K, Yamazaki H, Imiya K, et al. Relationship between CYP2C9 and 2C19 genotypes and tolbutamide methyl hydroxylation and S-mephenytoin 4′-hydroxylation activities in livers of Japanese and Caucasian populations. Pharmacogenetics. 1997;7(2):103-113.
244. Watanabe M, Iwahashi K, Kogoh T, et al. The relationship between phenytoin pharmacokinetics and the CYP2C19 genotype in Japanese epileptic patients. Clin Neuropharmacol. 1998;21(2):122-126.
245. Ibeanu G, Blaisdell J, Ferguson RJ, et al. A novel transversion in the intron 5 donor splice junction of CYP2C19 and a sequence polymorphism in exon 3 contribute to the poor metabolizer phenotype for the anticonvulsant drug S-mephenytoin. J Pharmacol Exp Ther. 1999;290(2):635-640.
246. Ruas JL, Lechner MC. Allele frequency of CYP2C19 in a Portuguese population. Pharmacogenetics. 1997;7(4):333-335.
247. de Morals SMF, Wilkinson GR, Blaisdell J, et al. The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. J Biol Chem. 1994;269(22):15419-15422.
248. Kubota T, Chiba K, Ishizaki T. Genotyping of S-mephenytoin 4′-hydroxylation in an extended Japanese population. Clin Pharmacol Ther. 1996;60(6):661-666.
249. Kaminsky LS, Zhang ZY. Human P450 metabolism of warfarin. Pharmacol Ther. 1997;73(1):67-74.
250. Lee CR, Goldstein JA, Pieper JA. Cytochrome P450 2C9 polymorphisms: a comprehensive review of the in-vitro and human data. Pharmacogenetics. 2002;12(3):251-263.
251. Schwarz UI. Clinical relevance of genetic polymorphisms in the human CYP2C9 gene. Eur J Clin Invest. 2003;33(Suppl. 2):23-30.
252. Rettie AE, Weinkers LC, Gonzales FJ, et al. Impaired (S)-warfarin metabolism catalysed by the R144C allelic variant of CYP2C9. Pharmacogenetics. 1994;4(1):39-42.
253. Haning RL, Hunter AP, Veronese ME, et al. Allelic variant of human cytochrome P450 2C9: baculovirus-mediated expression, purification, structural characterization, substrate stereoselectivity, and prochiral selectivity of the wild-type and I359L mutant forms. Arch Biochem Biophys. 1996;333(2):447-458.
254. Rettie AE, Haining RL, Bajpai M, et al. A common genetic basis for idiosyncratic toxicity of warfarin and phenytoin. Epilepsy Res. 1999;35(3):253-255.
255. Ieiri I, Tainaka H, Morita T, et al. Catalytic activity of three variants (He, Leu, and Thr) at amino acid residue 359 in human CYP2C9 gene and simultaneous detection using single-strand conformation polymorphism analysis. Ther Drug Monit. 2000;22(3):237-244.
256. 359 variants: enzyme kinetic study with seven substrates. Pharmacogenetics. 2000;10(2):95-104.
257. Dickman LJ, Rettie AE, Kneller MB, et al. Identification and functional characterization of a new CYP2C9 variant (CYP2C9*5) expressed among African Americans. Mol Pharmacol. 2001;60(2):382-387.
258. Tracy TS, Hutzler JM, Haining RL, et al. Polymorphic variants (CYP2C9*3 and CYP2C9*5) and the F114L active site mutation of CYP2C9: effect on atypical kinetic metabolism profiles. Drug Metab Dispos. 2002;30(4):385-390.
259. Steward DJ, Haning RL, Hanne KR, et al. Genetic association between sensitivity to warfarin and expression of CYP2C9*3. Pharmacogenetics. 1997;7(5):361-367.
260. Takahashi H, Kashima T, Momoto S, et al. Comparisons between in-vitro and in-vivo metabolism of S-warfarin: catalytic activities of cDNA-expressed CYP2C9, its LeU359 variant and their mixture versus unbound clearance in patients with the corresponding CYP2C9 genotypes. Pharmacogenetics. 1998;8(5):365-373.
261. Aithal GP, Day CP, Kesteven PJL, et al. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet. 1999;353(9154):717-719.
262. Halkin H, Lubetsky A. Warfarin dose requirement and CYP2C9 polymorphisms. Lancet. 1999;353(9168):1972-1973.
263. Ogg MS, Brennan P, Meade T, et al. CYP2C9*3 allelic variant and bleeding complications. Lancet. 1999;354(9184):1124.
264. Taube J, Haisall D, Baglin T. Influence of cytochrome p-450 CYP2C9 polymorphisms on warfarin sensitivity and risk of over-anticoagulation in patients on long-term treatment. Blood. 2000;96(5):1816-1819.
265. Loebstein R, Yonath H, Peleg D, et al. Interindividual variability in sensitivity to warfarin: nature or nurture? Clin Pharmacol Ther. 2001;70(2):159-164.
266. Takahashi H, Echizen H. Pharmacogenetics of warfarin elimination and its clinical implication. Clin Pharmacokinet. 2001;40(8):587-603.
267. Daly AK, Day CP, Aithal GP. CYP2C9 polymorphism and warfarin dose requirements. Br J Clin Pharmacol. 2002;53(4):408-409.
268. Higashi MK, Veenstra DL, Kondo LM, et al. Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. JAMA. 2002;287(13):1690-1698.
269. Linder MW, Looney S, Adams JE, et al. Warfarin dose adjustments based on CYP2C9 genetic polymorphisms. J Thromb Thrombolysis. 2002;14(3):227-232.
270. Scordo MG, Pengo V, Spina E, et al. Influence of CYP2C9 and CYP2C19 genetic polymorphisms on warfarin maintenance dose and metabolic clearance. Clin Pharmacol Ther. 2002;72(6):702-710.
271. Odani A, Hashimoto Y, Otsuki Y, et al. Genetic polymorphism of the CYP2C subfamily and its effect on the pharmacokinetics of phenytoin in Japanese patients with epilepsy. Clin Pharmacol Ther. 1997;62(3):287-292.
272. Aynacioglu AS, Brockmöller J, Bauer S, et al. Frequency of cytochrome P450 CYP2C9 variants in a Turkish population and functional relevance phenytoin. Br J Clin Pharmacol. 1999;48(3):409-415.
273. Kidd RS, Straughn AB, Meyer MCB, et al. Pharmacokinetics of chlorpheniramine, phenytoin, glipizide and nifedipine in an individual homozygous for the CYP2C9*3 allele. Pharmacogenetics. 1999;9(1);71-80.
274. McCrea JB, Cribb A, Rushmore T, et al. Phenotypic and genotypic investigations of a healthy volunteer deficient in the conversion of losartan to its active metabolite E-3174. Clin Pharmacol Ther. 1999;65(3):348-352.
275. Ninomiya H, Mamiya K, Matsuo S, et al. Genetic polymorphism of the CYP2C subfamily and excessive serum phenytoin concentration with central nervous system intoxication. Ther Drug Monit. 2000;22(2):230-232.
276. Thijssen HHW, Verkooijen IWC, Frank HLL. The possession of the CYP2C9*3 allele is associated with low dose requirement of acenocoumarol. Pharmacogenetics. 2000;10(8):757-760.
277. Brandolese R, Scordo MG, Spina E, et al. Severe phenytoin intoxication in a subject homozygous for CYP2C9*3. Clin Pharmacol Ther. 2001;70(4):391-394.
278. Thijssen HHW, Drittij MJ, Vervoort LMT, et al. Altered pharmacokinetics of R- and S-acenocoumarol in a subject heterozygous for CYP2C9*3. Clin Pharmacol Ther. 2001;70(3):292-298.
279. van der Weide D, Steijns LSW, Weelden MJM, et al. The effect of genetic polymorphism of cytochrome P450 CYP2C9 on phenytoin dose requirement. Pharmacogenetics. 2001;11(4):287-291.
280. Yoon Y, Shon J, Kirn M, et al. Frequency of cytochrome P450 2C9 mutant alleles in a Korean population. Br J Clin Pharmacol. 2001;51(3):277-280.
281. Kirchheiner J, Bauer S, Meineke I, et al. Impact of CYP2C9 and CYP2C19 polymorphisms on tolbutamide kinetics and the insulin and glucose response in healthy volunteers. Pharmacogenetics. 2002;12(2):101-109.
282. Miners J. CYP2C9 polymorphism: impact on tolbutamide pharmacokinetics and response. Pharmacogenetics. 2002;12(2):91-92.
283. Shon J, Yoon Y, Kim K, et al. Effects of CYP2C19 and CYP2C9 genetic polymorphisms on the disposition of and blood glucose lowering response to tolbutamide in humans. Pharmacogenetics. 2002;12(2):111-119.
284. Thijssen HHW, Ritzen B. Acenocoumarol pharmacokinetics in relation to cytochrome P450 2C9 genotype. CHn Pharmacol Ther. 2003;74(1):61-68.
285. Kirchheiner J, Kudlicz D, Meisel C, et al. Influence of CYP2C9 polymorphisms on the pharmacokinetics and cholesterol-lowering activity of (-)-3S,5R-fluvastatin and (+)-3R,5S-fluvastatin in healthy volunteers. Clin Pharmacol Ther. 2003;74(2):186-194.
286. Lee CR, Pieper JA, Frye RF, et al. Tolbutamide, flurbiprofen, and losartan as probes of CYP2C9 activity in humans. J Clin Pharmacol. 2003;2003(1):84-91.
287. Yu HCM, Chan TYK, Critchley J, et al. Factors determining the maintenance dose of warfarin in Chinese patients. Q J Med. 1996;89(2):127-135.
288. Takahashi H, Kashima T, Nomizo Y, et al. Metabolism of warfarin enantiomers in Japanese patients with heart disease having different CYP2C9 and CYP2C19 genotypes. Clin Pharmacol Ther. 1998;63(5):519-528.
289. Gross AS, Bridge S, Shenfield GM. Pharmacokinetics of tolbutamide in ethnic Chinese. Br J Clin Pharmacol. 1999;47(2):151-156.
290. Nasu K, Kubota T, Ishizaki T. Genetic analysis of CYP2C9 polymorphism in a Japanese population. Pharmacogenetics. 1997;7(5):405-409.
291. Xie HG, Prasad HC, Kim RB, et al. CYP2C9 allelic variants: ethnic distribution and functional significance. Adv Drug Deliv Rev. 2002;54(10):1257-1270.
292. Allabi AC, Gala JL, Desager JP, et al. Genetic polymorphisms of CYP2C9 and CYP2C19 in the Beninese and Belgian populations. Br J Clin Pharmacol. 2003;56(6):653-657.
293. Kimura M, Ieiri I, Mamiya K, et al. Genetic polymorphism of cytochrome P450s, CYP2C19, and CYP2C9 in a Japanese population. Ther Drug Monit. 1998;20(3):243-247.
294. Imai J, Ieiri I, Mamiya K, et al. Polymorphism of the cytochrome P450 (CYP) 2C9 gene in Japanese epileptic patients: genetic analysis of the CYP2C9 locus. Pharmacokinetics. 2000;10(1):85-89.
295. Yasar U, Akillu E, Canaparo R, et al. Analysis of CYP2C9*5 in Caucasian, Oriental and Black-African populations. Eur J Clin Pharmacol. 2002;58(8):555-558.
296. Leung AYH, Chow HCH, Kwong YL, et al. Genetic polymorphism in exon 4 of cytochrome P450 CYP2C9 may he associated with warfarin sensitivity in Chinese patients. Blood. 2001;98(6):2584-2587.
297. Takahashi H, Wilkinson GR, Caraco Y, et al. Population differences in S-warfarin metabolism between CYP2C9 genotype-matched Caucasian and Japanese Patients. Clin Pharmacol Ther. 2003;73(3):253-263.
298. Kolars JC, Lown KS, Schmiedlin-Ren P, et al. CYP3A gene expression in human gut epithelium. Pharmacogenetics. 1994;4(5):247-259.
299. Thummel KE, Wilkinson GR. In vitro and in vivo drug interactions involving human CYP3A. Annu Rev Pharmacol Toxicol. 1998;38:389-430.
300. de Wildt SN, Kearns GL, Leeder JS, et al. Cytochrome P450 3A (ontogeny and drug disposition). Clin Pharmacokinet 1999;37(6):485-505.
301. Guengerich FP. Cytochrome P-450 3A4: regulation and role in i drug metabolism. Annu Rev Pharmacol Toxicol. 1999;39:1-17.
302. Lin YS, Lockwood GF, Graham MA, et al. In-vivo phenotyping for CYP3A by a single-point determination of midazolam plasma concentration. Pharmacogenetics. 2001;11(9):781-791.
303. Gibbs MA, Hosea NA. Factors affecting the clinical development of cytochrome P450 3A substrates. Clin Pharmacokinet. 2003;42(1):969-984.
304. Domanski TL, Finta C, Halpert TR, et al. cDNA cloning and initial characterization of CYP3A43, a novel human cytochrome P450. Mol Pharmacol. 2001;59(2):386-392.
305. Gellner K, Eiselt R, Hustert E, et al. Genomic organization of the human CYP3A locus: identification of a new, inducible CYP3A gene. Pharmacogenetics. 2001;11(2):111-121.
306. Westlind A, Malmebo S, Johansson I, et al. Cloning and tissue distribution of a novel human cytochrome P450 of the CYP3A subfamily, CYP3A43. Biochem Biophys Res Commun. 2001;281(5):1349-1355.
307. Lamba JK, Lin YS, Schuetz EG, et al. Genetic contribution to variable human CYPSA-mediated metabolism. Adv Drug Deliv Rev. 2002;54(10):1271-1294.
308. Shimada T, Yamazaki H, Mimura M, et al. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther. 1994;270(1):414-423.
309. Ball SE, Scatina J, Kao J, et al. Population distribution and effects on drug metabolism of a genetic variant in the 5′ promoter region of CYP3A4. Clin Pharmacol Ther. 1999;66(3):288-294.
310. Sata F, Sapone A, Elizondo G, et al. CYP3A4 allelic variants with amino acid substitutions in exon 7 and 12: evidence for an allelic variant with altered catalytic activity. Clin Pharmacol Ther. 2000;67(1):48-56.
311. Wandel C, Witte JS, Hall JM, et al. CYP3A activity in African American and European American men: population differences and functional effect of the CYP3A4*1B 5′-promoter region polymorphism. Clin Pharmacol Ther. 2000;68(1):82-91.
312. Garcia-Martin E, Martinez C, Pizarro RM, et al. CYP3A4 variant alleles in white individuals with low CYP3A4 enzyme activity. Clin Pharmacol Ther. 2002;71(3):196-204.
313. Eiselt R, Domanski TL, Zibat A, et al. Identification and functional characterization of eight CYP3A4 protein variants. Pharmacogenetics. 2001;11(5):447-458.
314. van Schaik RHN, de Wildt SN, Brosens R, et al. The CYP3A4*3 allele: is it really rare? Clin Chem. 2001;47(6):1104-1106.
315. Schuetz EG, Schuetz JD, Grogan WM, et al. Expression of cytochrome P450 3A in amphibian, rat, and human kidney. Arch Biochem Biophys. 1992;294(1):206-214.
316. Haehner BD, Gorski JC, VandenBranden M, et al. Bimodal distribution of renal cytochrome P450 3A activity in humans. Mol Pharmacol. 1996;50(1):52-59.
317. Kuehl P, Zhang J, Lin Y, et al. Sequence diversity in CYP3A4 promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet. 2001;27(4):383-391.
318. Hustert E, Haberl M, Burk O, et al. The genetic determinants of the CYP3A5 polymorphism. Pharmacogenetics. 2001;11(9):773-779.
319. Fukuen S, Fukuda T, Maune H, et al. Novel detection assay by PCR-RFLP and frequency of the CYP3A5 SNPs, CYP3A5*3 and * 6 in a Japanese population. Pharmacogenetics. 2002;12(4):331-334.
320. Paulussen A, Lavrijsen K, Bohets H, et al. Two linked mutations in transcriptional regulatory elements of the CYP3A5 gene constitute the major genetic determinant of polymorphic activity in humans. Pharmacogenetics. 2000;10(5):415-424.
321. Lin YS, Dowling ALS, Quigley SD, et al. Co-regulation of CYP3A4 and CYP3A5 and contribution to hepatic and intestinal midazolam metabolism. Mol Pharmacol. 2002;62(1):162-172.
322. Shih PS, Huang JD. Pharmacokinetics of midazolam and 1′- hydroxymidazolam in Chinese with different CYP3A5 genotypes. Drug Metab Dispos. 2002;30(12):1491-1496.
323. Fukuda T, Onishi S, Fukunen S, et al. CYP3A5 genotype did not impact on nifedipine disposition in healthy volunteers. Pharmacogenomics J. 2004;4(1):34-39.
324. Goh BC, Lee SC, Wang LZ, et al. Explaining interindividual variability of docetaxel pharmacokinetics and pharmacodynamics in Asians through phenotyping and genotyping strategies. J Clin Oncol. 2002;20(17):3683-3690.
325. Williams JA, Ring BJ, Cantrell VE, et al. Comparative metabolic capabilities of CYP3A4, CYP3A5, and CYP3A7. Drug Metab Dispos. 2002;30(8):883-891.
326. Westlind-Johnsson A, Malmebo S, Johansson A, et al. Comparative analysis of CYP3A expression in human liver suggests only a minor role for CYP3A5 in drug metabolism. Drug Metab Dispos. 2003;31(6):755-761.
327. Lin Y, Anderson GD, Kantor E, et al. Differences in the urinary excretion of 6-β-hydroxycortisol/cortisol between Asian and Caucasian women. J Clin Pharmacol. 1999;39(6):578-582.
328. Ged C, Rouillon JM, Pichard L, et al. The increase in urinary excretion of 6βhydroxycortisol as a marker of human hepatic cytochrome P450IIIA induction. Br J Clin Pharmacol. 1989;28(4):373-387.
329. Nemeroff CB, DeVane CL, Pollock BG. Newer antidepressants and the cytochrome P450 system. Am J Psychiatry. 1996;153(3):311-320.
330. Yasui N, Otani K, Kaneko S, et al. A kinetic and dynamic study of oral alprazolam with and without erythromycin in humans: in vivo evidence for the involvement of CYP3A4 in alprazolam metabolism. Clin Pharmacol Ther. 1996;59(5):514-519.
331. Venkatakrishnan K, Greenblatt DJ, von Moltke L, et al. Alprazolam is another substrate for human cytochrome P450-3A isoforms. J Clin Psychopharmacol. 1998;18(3):256.
332. Gorski JC, Jones DR, Hamman MA, et al. Biotransformation of alprazolam by members of the human cytochrome P4503A subfamily. Xenobiotica. 1999;29(9):931-944.
333. Lin KM, Lau JK, Smith R, et al. Comparison of alprazolam plasma levels in normal Asian and Caucasian male volunteers. Psychopharmacology. 1988;96(3):365-369.
334. Yu K, Cho J, Shon J, et al. Ethnic differences and relationships in the oral pharmacokinetics of nifedipine and erythromycin. Clin Pharmacol Ther. 2001;70(3):228-236.
335. Ahsan CH, Renwick AG, Macklin B, et al. Ethnic differences in the pharmacokinetics of oral nifedipine. Br J Clin Pharmacol. 1991;31(4):399-403.
336. Ahsan CH, Renwick AG, Waller DG, et al. The influences of dose and ethnic origins on the pharmacokinetics of nifedipine. Clin Pharmacol Ther. 1993;54(3):329-338.
337. Rashid TJ, Martin U, Clarke H, et al. Factors affecting the absolute bioavailability of nifedipine. Br J Clin Pharmacol. 1995;40(1):51-58.
338. Sowunmi A, Rashid TJ, Akinyinka OO, et al. Ethnic differences in nifedipine kinetics: comparisons between Nigerians, Caucasians and South Asians. Br J Clin Pharmacol. 1995;40(5):489-493.
339. Aoyama T, Yamano S, Waxman DJ, et al. Cytochrome P-450 hPCN3, a novel cytochrome P-450 IIIA gene product that is differentially expressed in adult human liver. J Biol Chem. 1989;264(18):10388-10395.
340. Wrighton SA, Brian WR, Sari MA, et al. Studies on the expression and metabolic capabilities of human liver cytochrome P450IIIA5(HLp3). Mol Pharmacol. 1990;38(2):207-213.
341. Wandel C, Böcker R, Böhrer H, et al. Midazolam is metabolized by at least three different cytochrome P450 enzymes. Br J Anaesth. 1994;73(5):658-661.
342. Gillam EMJ, Wunsch RM, Ueng YF, et al. Expression of cytochrome P450 3A7 in Escherichia coli: effects of 5′ modification and catalytic characterization of recombinant enzyme expressed in bicistronic format with NADPH-cytochrome P450 reductase. Arch Biochem Biophys. 1997;346(1):81-90.
343. Foster TS, Hamann SR, Richards VR, et al. Nifedipine kinetics and bioavailability after single intravenous and oral doses in normal subjects. J Clin Pharmacol. 1983;23(4):161-170.
344. Waller DG, Renwick AG, Gruchy BS, et al. The first pass metabolism of nifedipine in man. Br J Clin Pharmacol. 1984;18(6):951-954.
345. 14C-repaglinide during repaglinide multiple dosing. Eur J Clin Pharmacol. 1999;55(7):521-525.
346. Bidstrup TB, Bjornsdottir I, Sidelmann UG, et al. CYP2C8 and CYP3A4 are the principal enzymes involved in the human in vitro biotransformation of the insulin secretagogue repaglinide. Br J Clin Pharmacol. 2003;56(3):305-314.
347. Thomsen MS, Chassard D, Evène E, et al. Pharmacokinetics of repaglinide in healthy Caucasian and Japanese subjects. J Clin Pharmacol. 2003;43(1):23-28.
348. Venkatakrishnan K, von Moltke LL, Duan SX, et al. Kinetic characterization and identification of the enzymes responsible for the hepatic biotransformation of adinazolam and N-desmethyladinazolam in man. J Pharm Pharmacol. 1998;5(3):265-274.
349. Ajir K, Smith M, Lin K, et al. The pharmacokinetics and pharmacodynamics of adinazolam: multi-ethnic comparisons. Psychopharmacology. 1997;129(3):265-270.
350. Mück W, Unger S, Kawano K, et al. Inter-ethnic comparisons of the pharmacokinetics of the HMG-CoA reductase inhibitor cerivastatin. Br J Clin Pharmacol. 1998;45(6):583-590.
351. Tateishi T, Watanabe M, Nakura H, et al. CYP3A activity in European American and Japanese men using midazolam as an in vivo probe. Clin Pharmacol Ther. 2001;69(5):333-339.
352. Kinirons MT, Lang CC, He HB, et al. Triazolam pharmacokinetics and pharmacodynamics in Caucasians and Southern Asians: ethnicity and CYP3A activity. Br J Clin Pharmacol. 1996;41(1):69-72.
353. Fuhr U, Doehmer J, Battula N, et al. Biotransformation of caffeine and theophylline in mammalian cell lines genetically engineered for expression of single cytochrome P450 isoforms. Biochem Pharmacol. 1992;43(2):225-235.
354. Lemoine A, Gautier JC, Azoulay D, et al. Major pathway of imipramine metabolism is catalyzed by cytochromes P-450 1A2 and P-450 3A4 in human liver. Mol Pharmacol. 1993;43(5):827-832.
355. Bertilsson L, Carrilo JA, Dahl ML, et al. Clozapine disposition covaries with CYP1A2 activity determined by a caffeine test. Br J Clin Pharmacol. 1994;38(5):471-473.
356. Butler MA, Lang NP, Young JF, et al. Determination of CYP1A2 and NAT2 phenotypes in human populations by analysis of caffeine urinary metabolites. Pharmacogenetics. 1992;2(3):116-127.
357. Vistisen K, Poulsen HE, Loft S. Foreign compound metabolism capacity in man measured from metabolites of dietary caffeine. Carcinogenesis. 1992;13(9):1561-1568.
358. Welfare MR, Aitkin M, Bassendine MF, et al. Detailed modelling of caffeine metabolism and examination of the CYP1A2 gene: lack of a polymorphism in CYP1A2 in Caucasians. Pharmacogenetics. 1999;9(3):367-375.
359. Jerling M, Lindström M, Bondesson U, et al. Fluvoxamine inhibition and carbamazepine induction of the metabolism of clozapine: evidence from a therapeutic drug monitoring service. Ther Drug Monit. 1994;16:368-374.
360. Chong SA, Tan CH, Khoo YM, et al. Clinical evaluation and plasma clozapine concentrations in Chinese patients with schizophrenia. Ther Drug Monit. 1997;19(2):219-223.
361. Grant DM, Tang BK, Kalow W. Variability in caffeine metabolism. Clin Pharmacol Ther. 1983;33(5):591-602.
362. Marchand LL, Franke AA, Custer L, et al. Lifestyle and nutritional correlates of cytochrome CYP1A2 activity: inverse associations with plasma lutein and alpha-tocopherol. Pharmacogenetics. 1997;7(1):11-19.
363. Pelkonen O, Rautio A, Raunio H, et al. CYP2A6: a human coumarin 7-hydroxylase. Toxicology. 2000;144(1-3):139-147.
364. Nakajima M, Yamagishi S, Yamamoto H, et al. Deficient cotinine formation from nicotine is attributed to the whole deletion of the CYP2A6 gene in humans. Clin Pharmacol Ther. 2000;67(1):57-69.
365. Nakajima M, Yamamoto T, Nunoya K, et al. Role of human cytochrome P45602A6 in C-oxidation of nicotine. Drug Metab Dispos. 1996;24(11):1212-1217.
366. Messina ES, Tyndale RF, Sellers EM. A major role for CYP2A6 in nicotine C-oxidation by human liver microsomes. J Pharmacol Exp Ther. 1997;282(3):1608-1614.
367. Oscarson M. Genetic polymorphisms in the cytochrome P450 2A6(CYP2A6) gene: implications for interindividual differences in nicotine metabolism. Drug Metab Dispos. 2001;29(2):91-95.
368. Kitagawa K, Kunugita N, Katoh T, et al. The significance of the homozygous CYP2A6 deletion on nicotine metabolism: a new genotyping method of CYP2A6 using a single PCR-RFLP. Biochem BiophysRes Commun. 1999;262(1):146-151.
369. Pianezza ML, Seller EM, Tyndale RF. Nicotine metabolism defect reduces smoking. Nature. 1998;393(6687):750.
370. London SJ, Idle JR, Daly AK, et al. Genetic variation of CYP2A6, smoking, and risk of cancer. Lancet. 1999;353(9156):898-890.
371. Sabol SZ, Hamer DH. An improved assay shows no association between the CYP2A6 gene and cigarette smoking behavior. Behav Genet. 1999;29(4):257-261.
372. Miyamoto M, Umetsu Y, Dosaka-Akita H, et al. CYP2A6 gene deletion reduces susceptibility to lung cancer. Biochem Biophys Res Commun. 1999;261(3):658-660.
373. Pirisi A. Nicotine metabolism varies between different ethnic groups. Lancet. 2002;359(9371):234.
374. Benowitz NL, Pérez-Stable EJ, Herrera B, et al. Slower metabolism and reduced intake of nicotine from cigarette smoking in Chinese-Americans. J
375. Fernadez-Salgyero P, Huffman SMG, Cholerton S, et al. A genetic polymorphism in coumarin 7-hydroxylation: sequence of the human CYP2A genes identification of variant CYP2A6 alleles. Am J Hum Genet. 1995;57(3):651-660.
376. Oscarson M, Gullstén H, Rautio A, et al. Genotyping of human cytochrome P450 2A6 (CYP2A6), a nicotine C-oxidase. FEBS Lett. 1998;438(3):201-205.
377. Chen GF, Tang YM, Green B, et al. Low frequency of CYP2A6 gene polymorphism as revealed by a one-step polymerase chain reaction method. Pharmacogenetics. 1999;9(3):327-332.
378. Oscarson M, McLellan RA, Gullstén H, et al. Characterisation and PCR-based detection of a CYP2A6 gene deletion found at a high frequency in a Chinese population. FEBS Lett. 1999;448(1):105-110.
379. Oscarson M, McLellan RA, Gullstén H, et al. Identification and characterisation of novel polymorphisms in aie CYP2A locus: implications for nicotine metabolism. FEBS Lett. 1999;460(2):321-327.
380. Ariyoshi N, Takahashi Y, Miyamoto M, et al. Structural characterization of a new variant of the CYP2A6 gene (CYP2A6*1B) apparently diagnosed as hétérozygotes of CYP2A6*A and CYP2A6*4C. Pharmacogenetics. 2000;10(8):687-693.
381. Bourian M, Gullstén H, Legrum W. Genetic polymorphism of CYP2A6 in the German population. Toxicology. 2000;144(1-3):129-137.
382. Kwon JT, Nakajima M, Chai S, et al. Nicotine metabolism and CYP2A6 allele frequencies in Koreans. Pharmacogenetics. 2001;11(4):317-323.
383. Nakajima M, Kwon JT, Tanaka N, et al. Relationship between interindividual differences in nicotine metabolism and CYP2A6 genetic polymorphism in humans. Clin Pharmacol Ther. 2001;68(1):72-78.
384. Raunio H, Rautio A, Gullstén H, et al. Polymorphisms of CYP2A6 and its practical consequences. Br J Clin Pharmacol. 2001;52(4):357-363.
385. Inoue K, Yamazaki H, Shimada T. CYP2A6 genetic polymorphisms and liver microsomal coumarin and nicotine oxidation activities in Japanese and Caucasians. Arch Toxicol. 2000;73(10-11):532-539.
386. Pitarque M, von Richter O, Oke B, et al. Identification of a single nucleotide polymorphism in the TATA box of the CYP2A6 gene: impairment of its promoter activity. Biochem Biophys Res Commun. 2001;284(2):455-460.
387. Xu C, Rao YS, Xu B, et al. An in vivo pilot study characterizing the new CYP2A6*7, *8, and *10 alleles. Biochem Biophys Res Commun. 2002;290(1):318-324.
388. Sweet DH, Bush KT, Nigam SK. The organic anion transporter family: from physiology to ontogeny and the clinic. Am J Physiol Renal Physiol. 2001;281(2):F197-F205.
389. Zhou HH, Sheller JR, Nu H, et al. Ethnic differences in response to morphine. Clin Pharmacol Ther. 1993;54(5):507-513.
390. Hu OYP, Ding PYA, Huang CSH, et al. Pharmacokinetics of fosinoprilat in Chinese and whites after intravenous administration. J Clin Pharmacol. 1997;37(9):834-840.